Lexology September 16, 2025
Many of President Trump’s executive orders (EOs) and legislative measures have been designed to curtail federal regulation, reduce the size of the administrative state, and withdraw the U.S. from multilateral institutions. Here we examine how the President’s policy agenda—along with the approach of U.S. health secretary Robert F. Kennedy Jr—is impacting the U.S. Food and Drug Administration
The Trump administration’s policy agenda, the approach of U.S. health secretary Robert F. Kennedy Jr., and the work of the Department of Government Efficiency (DOGE), are upending the way pharmaceutical products, medical devices and healthcare innovations are evaluated and approved in the United States.
Several of President Trump’s more than 150 executive orders (EOs) signed during his early months in office have a...
Today's Sponsors
Today's Sponsor